No Data
No Data
We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative
Chongqing Lummy Pharmaceutical: Half-year report for the year 2024.
Chongqing Lummy Pharmaceutical: Summary of Half-Year Report in 2024.
Chongqing Lummy Pharmaceutical (300006.SZ): The net income for the first half of the year is 1.3282 million yuan, turning losses into profits year-on-year.
Chongqing Lummy Pharmaceutical (300006.SZ) released its semi-annual report for 2024, achieving a revenue of CNY 0.382 billion, a decrease of 15.89% compared to the same period last year; the net income attributable to shareholders of the listed company was CNY 1.3282 million, turning losses into gains year-on-year.
As of July 10th, Chongqing Lummy Pharmaceutical (300006.SZ) had a shareholder count of 31,391.
On July 15th, Gelunhui reported that as of July 10th, 2024, the number of shareholders in Chongqing Lummy Pharmaceutical (300006.SZ) was 31,391 on the investor interaction platform.
Chongqing Lummy Pharmaceutical (300006.SZ): The Replicor hepatitis B drug development project is currently steadily progressing.
Chongqing Lummy Pharmaceutical (300006.SZ) stated on the investor interaction platform on June 12 that the company holds 0.75% equity of Replicor Company through its wholly-owned subsidiary Lai Mei Hong Kong. Replicor Company's hepatitis B drug development project is currently making steady progress, and the company will closely monitor the progress of the project and fulfill its information disclosure obligations in a timely manner in accordance with the relevant regulations of the Shenzhen Stock Exchange.
No Data